A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

To join this study, participants need to be at least 40 years old and have a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF). You might be eligible whether you are currently taking approved medicines for IPF (like nintedanib or pirfenidone) or not taking any such medicine.

There are also some health requirements related to your lung function. Your forced vital capacity (FVC), which measures how much air you can breathe out after a deep breath, needs to be at least 45% of what's expected for someone your age and size. Your DLCO (diffusion capacity of the lung for carbon monoxide), which measures how well oxygen gets into your blood from your lungs, also needs to be at least 25% of what's expected.

However, you wouldn't be able to join if you have lung disease other than IPF, or if your lung scans show more emphysema than scarring. You also couldn't take part if you've recently had a sudden worsening of your IPF, a chest infection, certain heart problems (like a recent heart attack or heart failure), or if you've had an organ transplant or are likely to need a lung transplant.

If you decide to take part, you would be involved in this study for about 24 weeks, which is roughly six months. During this time, you would receive either a specific dose of AZD8965 or a placebo (a dummy drug). Neither you nor your study doctor would know which one you are receiving – this is called 'double-blind' and helps ensure the results are fair.

You would have several visits to the clinic for various checks and tests. These might include blood tests, lung function tests (like the ones you already have for IPF), and assessments of how you are feeling. The study team will explain exactly what each visit involves, how much time it will take, and when you need to come in. You would be given the study medication to take as instructed by the study team.